SCHEMBL3292248

SCHEMBL3292248

Cc1ccc(S(=O)(=O)Nc2ncncc2OCc2ccc3c(c2)OCCN3C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ HDAC3 O15379 2/20 0.43
▸ HDAC4 P56524 2/20 0.43
▸ HDAC1 Q13547 2/20 0.43
▸ HDAC7 Q8WUI4 2/20 0.43
▸ HDAC2 Q92769 2/20 0.43
▸ HDAC10 Q969S8 2/20 0.43
▸ HDAC11 Q96DB2 2/20 0.43
▸ HDAC8 Q9BY41 2/20 0.43
▸ HDAC6 Q9UBN7 2/20 0.43
▸ HDAC9 Q9UKV0 2/20 0.43
▸ HDAC5 Q9UQL6 2/20 0.43
▸ PDE10A Q9Y233 1/20 0.43
▸ PTGES2 Q9H7Z7 1/20 0.42
▸ PKM P14618 1/20 0.40
▸ SCN9A Q15858 4/20 0.39
▸ GHSR Q92847 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3299669 0.87 KMT2A (0.45) KMT2AALDH1A1HTTRECQLHDAC3
SCHEMBL3298267 0.84 TP53 (0.43) ALDH1A1HTTRECQLHDAC3HDAC4
SCHEMBL3297058 0.84 TP53 (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3294541 0.84 CCR4 (0.46) KMT2AALDH1A1HTTRECQLHDAC3
SCHEMBL3294748 0.83 CCR4 (0.46) PDE10APTGES2
SCHEMBL3294195 0.82 PTGDR2 (0.47) ALDH1A1HTTRECQLPDE10APTGES2
SCHEMBL3291732 0.81 KDM4E (0.46) KMT2AALDH1A1HTTRECQLHDAC3
SCHEMBL3295500 0.81 ALDH1A1 (0.44) KMT2AALDH1A1HTTRECQLHDAC3
SCHEMBL3293821 0.80 ALDH1A1 (0.43) KMT2AALDH1A1HTTRECQLHDAC3
SCHEMBL3295692 0.78 TP53 (0.48) KMT2APKMSCN9ALMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-21 — — US disclosed
US-7732442-B2 Chemokine receptor antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 — — US disclosed
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 — — US disclosed
EP-1661889-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF CCR5, CCR4, CCR1 KMT2A 4641/4885ALDH1A1 2497/4885HTT 4247/4885
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof CCR5, CCR4, CCR1 KMT2A 4641/4885ALDH1A1 2497/4885HTT 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback